Clin Cancer Res. 2020 Sep 21:clincanres.2901.2020. doi: 10.1158/1078-0432.CCR-20-2901. Online ahead of print.
Most colorectal cancers are microsatellite stable with no response to anti-PD-1 therapy, necessitating the development of new immunomodulatory treatment strategies. Co-inhibition of anti-PD-1 and STAT3 can elicit an effective anti-tumor response in a small subset of microsatellite stable colorectal cancer patients, and biomarkers predictive of response are under investigation.